SAN FRANCISCO A pharmaceutical company may have chosen an imperfect methodology to present its clinical trial results, but that alone is not enough to plead a violation of securities laws, the U.S. Court of Appeals for the Ninth Circuit ruled Thursday.
The decision in In re Rigel Pharmaceutical Securities Litigation appeared to create a strong level of protection for pharmaceutical companies against claims that they didn’t present results of clinical trials in the fairest possible light. Neither the U.S. Supreme Court nor the Ninth Circuit had addressed the issue previously, according to Ninth Circuit Senior Judge Procter Hug Jr.’s opinion.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
